Proliferative lupus nephritis (LN) progresses to end-stage kidney disease (ESKD) in roughly 10% of the cases despite treatment. Other than achieving <0.8 g/24h proteinuria at 12 months after treatment, early biomarkers predicting ESKD or death are lacking. Recent studies encompassing not only LN have highlighted the central role of the alternative complement pathway (ACP), with or without histological evidence of thrombotic microangiopathy (TMA), as a key promotor of renal death.
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis / Rossi, Giovanni Maria; Maggiore, Umberto; Peyronel, Francesco; Fenaroli, Paride; Delsante, Marco; Benigno, Giuseppe Daniele; Gianfreda, Davide; Urban, Maria Letizia; Manna, Zerai; Arend, Lois Johanna; Bagnasco, Serena; Vaglio, Augusto; Fiaccadori, Enrico; Rosenberg, Avi Z; Hasni, Sarfaraz; Manenti, Lucio. - In: KIDNEY INTERNATIONAL REPORTS. - ISSN 2468-0249. - ELETTRONICO. - 7:(2022), pp. 2647-2656. [10.1016/j.ekir.2022.09.012]
Persistent Isolated C3 Hypocomplementemia as a Strong Predictor of End-Stage Kidney Disease in Lupus Nephritis
Peyronel, Francesco;Urban, Maria Letizia;Vaglio, Augusto;
2022
Abstract
Proliferative lupus nephritis (LN) progresses to end-stage kidney disease (ESKD) in roughly 10% of the cases despite treatment. Other than achieving <0.8 g/24h proteinuria at 12 months after treatment, early biomarkers predicting ESKD or death are lacking. Recent studies encompassing not only LN have highlighted the central role of the alternative complement pathway (ACP), with or without histological evidence of thrombotic microangiopathy (TMA), as a key promotor of renal death.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2468024922017739-main.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
873.67 kB
Formato
Adobe PDF
|
873.67 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
